Moderna Inc

Moderna Inc

MRNA · NASDAQ · Healthcare / Biotechnology

223.37USD-7.98 (-3.45%)

Price History

Full chart

Market Stats

Previous Close231.35
Open224.90
Day Range221.70 – 231.35
52-Week Range22.28 – 258.72
Volume8.09M
Market Cap91.20B
P/E (TTM)0.00
Forward P/E23.04
EPS-7.98
Dividend Yield0.00%
Beta1.17
50-Day Avg184.00
200-Day Avg87.49

About

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Stéphane Bancel M.B.A.
  • Employees4.70K
  • Headquarters325 Binney Street, Cambridge, MA, United States, 02142, USA
  • Websitehttps://www.modernatx.com

Leadership

  • Mr. Stéphane Bancel M.B.A.CEO & Director · b. 1973
  • Dr. Stephen Hoge M.D.President · b. 1976
  • Mr. James M. MockChief Financial Officer · b. 1977
  • Ms. Shannon Thyme Klinger J.D.Chief Legal Officer & Corporate Secretary · b. 1971
  • Mr. Juan AndresChief Operating Officer · b. 1965
  • Ms. Lavina Talukdar CFASenior VP & Head of Investor Relations · b. 1974
  • Chris RidleyVP & Global Head of Communications
  • Ms. Tracey FranklinChief People & Digital Technology Officer · b. 1980
  • Dr. Charbel Haber M.P.H., Ph.D.Senior VP & Head of Global Regulatory Science
  • Mr. Patrick Norman BergstedtSenior Vice President of Commercial Vaccines · b. 1962

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue500.00K0108.40M205.82M122.51M48.04M274.49M17.74B18.88B6.85B3.20B1.94B
Growth (%)--100.00%-+89.88%-40.48%-60.79%+471.43%+6361.44%+6.42%-63.72%-53.29%-39.23%
Cost of Revenue0015.11M20.54M454.08M496.31M7.93M2.62B5.42B4.69B1.46B868.00M
Gross Profit500.00K093.28M185.29M-331.57M48.04M266.56M15.12B13.46B2.15B1.74B1.08B
Gross Margin100.00%-86.06%90.02%-270.64%100.00%97.11%85.24%71.31%31.47%54.24%55.35%
Operating Expense4.02M1.11M317.05M454.64M81.70M593.76M1.03B1.82B4.04B6.39B5.68B4.15B
Operating Income-3.52M-1.11M-223.77M-269.36M-413.27M-545.72M-763.14M13.30B9.42B-4.24B-3.94B-3.07B
Operating Margin-704.00%--206.44%-130.87%-337.33%-1136.06%-278.02%74.97%49.91%-61.90%-123.32%-158.13%
EBITDA---208.66M-235.33M-388.40M-514.70M-731.89M13.53B9.95B-3.28B-3.39B-2.55B
EBITDA Margin---192.50%-114.33%-317.03%-1071.49%-266.64%76.27%52.73%-47.94%-106.10%-131.33%
Net Income-6.48M-1.11M-216.21M-255.92M-384.73M-514.02M-747.06M12.20B8.36B-4.71B-3.56B-2.82B
Net Income Margin-1295.40%--199.46%-124.34%-314.04%-1070.07%-272.16%68.80%44.30%-68.84%-111.32%-145.16%
R&D686.00K322.32K274.72M410.46M454.08M496.31M1.37B1.99B3.29B4.84B4.54B3.13B
R&D as % of Total Revenue137.20%-253.44%199.42%370.64%1033.20%499.23%11.23%17.46%70.75%142.01%161.11%
Interest Expense000132.00K3.10M6.61M9.89M18.00M29.00M38.00M24.00M10.00M
Interest Expense % of Total Revenue0.00%-0.00%0.06%2.53%13.76%3.60%0.10%0.15%0.55%0.75%0.51%

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.22M261.85K1.42B1.08B1.96B1.59B7.34B24.67B25.86B18.43B14.14B12.34B
Total Liabilities13.59M171.66K575.31M459.19M431.91M414.61M4.78B10.52B6.74B4.57B3.24B3.69B
Total Equity-4.37M90.19K841.85M625.30M1.53B1.17B2.56B14.14B19.12B13.85B10.90B8.65B
Cash1.82M261.85K50.08M134.86M658.36M235.88M2.62B6.85B3.21B2.91B1.93B2.60B
Total Debt--37.55M88.40M112.56M132.36M237.00M916.00M1.20B1.24B747.00M1.92B
Net Debt---37.58M-119.17M-624.88M-103.51M-2.39B-5.93B-2.00B-1.66B-1.18B-679.00M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.78M-738.15K66.73M-331.48M-330.87M-458.97M2.03B13.62B4.98B-3.12B-3.00B-1.87B
Investing Cash Flow5.87K5.87K-648.61M416.10M-372.47M-14.95M-1.67B-8.52B-5.18B4.21B1.95B1.95B
Financing Cash Flow5.69M1.00M472.91M168.00K1.23B51.12M2.03B-873.00M-3.45B-1.38B56.00M593.00M
Capital Expenditure0033.14M58.40M105.77M31.55M67.45M284.00M400.00M707.00M1.05B192.00M
Free Cash Flow--33.59M-389.88M-436.63M-490.52M1.96B13.34B4.58B-3.83B-4.05B-2.06B
Dividends Paid--633.00K1.48M--7.04M124.00M184.00M270.00M--
FCF to OCF--50.33%117.62%131.97%106.87%96.67%97.91%91.97%122.67%134.99%110.25%
Dividend Paid to FCF--1.88%-0.38%--0.36%0.93%4.02%-7.06%--

Earnings

Report DateJun 30, 2018Dec 7, 2018Mar 6, 2019May 9, 2019Aug 8, 2019Nov 6, 2019Feb 26, 2020May 7, 2020Aug 5, 2020Oct 29, 2020Feb 25, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Feb 24, 2022May 4, 2022Aug 3, 2022Nov 3, 2022Feb 23, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Feb 22, 2024May 2, 2024Aug 1, 2024Nov 7, 2024Feb 14, 2025Feb 20, 2025May 1, 2025Aug 1, 2025Nov 6, 2025Feb 13, 2026Apr 30, 2026May 1, 2026Jul 31, 2026Nov 5, 2026Nov 6, 2026
EPS Estimate-0.00-0.36-0.36-0.45-0.44-0.42-0.36-0.36-0.37-0.352.475.869.429.905.624.493.114.60-1.77-4.12-2.05-0.97-3.57-3.35-1.90-2.76-2.76-3.11-3.00-2.16-2.64-2.11-2.11-1.97-1.10-1.10
EPS Actual-0.29-0.52-1.78-0.40-0.41-0.37-0.37-0.35-0.31-0.59-0.692.846.467.7011.298.585.242.533.610.19-3.62-9.530.55-3.07-3.330.03-2.91-2.91-2.52-2.13-0.51-2.11-3.40-3.40-1.97--
Surprise---394.44%-11.11%8.89%15.91%11.90%2.78%13.89%-59.46%-97.14%14.98%10.24%-18.26%14.04%52.67%16.70%-18.65%-21.52%110.73%12.14%-364.88%156.70%14.01%0.60%101.58%-5.44%-5.44%18.97%29.00%76.39%20.08%-61.14%-61.14%0.00%--
Timing-After-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap91.20B
Enterprise Value84.31B
Trailing P/E0.00
Forward P/E23.04
PEG Ratio0.00
Price / Sales40.93
Price / Book13.04
EPS-7.98
Book Value16.95
Revenue (TTM)2.23B
Gross Profit (TTM)-1.47B
EBITDA-2.20B
Profit Margin-141.43%
Operating Margin-557.93%
Return on Equity-39.00%
Return on Assets-13.26%
Shares Outstanding399.24M
Shares Float371.98M
Beta1.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 23 analystsTarget 138.37
  • Strong Buy
    3
  • Buy
    1
  • Hold
    16
  • Sell
    1
  • Strong Sell
    2

Ownership Breakdown

Institutions
80.51%
Insiders
7.36%
Retail / Other
12.13%

Top Institutional Holders

  • FMR Inc
    51.86M12.99%
  • BlackRock Inc
    30.60M7.66%
  • Vanguard Capital Management, LLC
    23.21M5.81%
  • Capital World Investors
    22.28M5.58%
  • Baillie Gifford & Co Limited.
    18.21M4.56%
  • State Street Corp
    15.73M3.94%
  • Vanguard Portfolio Management, LLC
    15.58M3.90%
  • Geode Capital Management, LLC
    9.71M2.43%
  • Morgan Stanley - Brokerage Accounts
    9.54M2.39%
  • Theleme Partners LLP
    8.06M2.02%
  • Two Sigma Investments LLC
    7.19M1.80%
  • Amvescap Plc.
    5.78M1.45%
  • T. Rowe Price Associates, Inc.
    5.59M1.40%

Top Fund Holders

  • American Funds Growth Fd of Amer A
    14.98M3.75%
  • Vanguard MStar Total Stk Mkt Idx Invest
    11.41M2.86%
  • Vanguard 500 Index Investor
    9.76M2.44%
  • Invesco QQQ Trust
    8.30M2.08%
  • Fidelity Growth Company Fund
    8.24M2.06%
  • Scottish Mortgage Ord
    7.40M1.85%
  • Fidelity OTC
    5.19M1.30%